Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$110.94 USD
+1.05 (0.96%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$110.94 USD
+1.05 (0.96%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
BD (BDX) Q3 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
BD's (BDX) overall topline benefits from revenue growth in all segments in the fiscal third quarter.
Avanos (AVNS) Q2 Earnings Top Estimates, Gross Margin Contracts
by Zacks Equity Research
Strength in Avanos' (AVNS) Digestive Health segment drives its second-quarter performance.
Medtronic Stock Moves Above 50-Day SMA: Should You Buy MDT?
by Urmimala Biswas
Medtronic's (MDT) stock finally breaking above its 50-day SMA can be a piece of good news for investors, signaling an uptrend.
Labcorp (LH) Q2 Earnings Surpass Estimates, Margins Increase
by Zacks Equity Research
Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.
Exact Sciences (EXAS) Q2 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Exact Sciences' (EXAS) second-quarter 2024 top-line results reflect robust revenues from the Screening and Precision Oncology segments.
QIAGEN (QGEN) Q2 Earnings Surpass Estimates, Margins Crash
by Zacks Equity Research
QIAGEN's (QGEN) earnings and revenues beat estimates in the second quarter. The company remains bullish on solid growth trends in the core business.
Waters (WAT) Q2 Earnings & Sales Beat Estimates, Fall Y/Y
by Zacks Equity Research
Waters' (WAT) second-quarter results are hurt by weak end-market momentum and softness in Asia, Americas and Europe.
Penumbra (PEN) Tops on Q2 Earnings, Lowers Sales View
by Zacks Equity Research
Penumbra's (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.
Neogen (NEOG) Q4 Earnings Miss Estimates, Margins Crash
by Zacks Equity Research
Neogen's (NEOG) Food Safety and Animal Safety businesses witness a year-over-year decrease in revenues in the fourth quarter of fiscal 2024.
Integra's (IART) Q2 Earnings and Revenues Top, Margins Down
by Zacks Equity Research
Integra's (IART) second-quarter 2024 results reflect strong demand for its diverse portfolio of leading brands and the continued successful market adoption of CereLink.
Philips (PHG) Q2 Earnings Rise, Revenues Fall Year Over Year
by Zacks Equity Research
Philips' (PHG) second-quarter results benefit from strong momentum across the Diagnosis & Treatment, Connected Care and Personal Health businesses.
Brokers Suggest Investing in Abbott (ABT): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for Abbott (ABT) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Hologic (HOLX) Q3 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Hologic (HOLX) delivers strong performances across all its franchises in the third quarter of fiscal 2024.
Integer Holdings (ITGR) Q2 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Integer Holdings' (ITGR) second-quarter results reflect robust Medical Sales, along with strength in all the product lines.
ICON (ICLR) Q2 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
ICON's (ICLR) second-quarter 2024 results reflect efficient service delivery and strong cost control.
Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Down
by Zacks Equity Research
Amedisys (AMED) delivers year-over-year growth in all three of its segmental revenues in the second quarter of 2024.
The Zacks Analyst Blog Highlights SAP, Abbott Laboratories, Citigroup, Team and Vaso
by Zacks Equity Research
SAP, Abbott Laboratories, Citigroup, Team and Vaso are part of the Zacks top Analyst Blog.
Align Technology (ALGN) Beats on Q2 Earnings, Lowers '24 Sales View
by Zacks Equity Research
Align Technology's (ALGN) records second-quarter 2024 revenue growth across all regions. This was mostly due to a robust performance by the Imaging Systems & CAD/CAM Services business segment.
Edwards Lifesciences (EW) Q2 Earnings Meet Mark, Margins Crash
by Zacks Equity Research
Edwards Lifesciences (EW) reports strong contributions from the TMTT product group in the second quarter of 2024.
Chemed (CHE) Q2 Earnings Miss Estimates, Margins Expand
by Zacks Equity Research
Chemed's (CHE) VITAS segment delivers impressive revenue growth and margin expansion in the second quarter of 2024.
Top Analyst Reports for SAP, Abbott Laboratories & Citigroup
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including SAP SE (SAP), Abbott Laboratories (ABT) and Citigroup Inc. (C), as well as two micro-cap stocks Team, Inc. (TISI) and Vaso Corporation (VASO).
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Quest Diagnostics (DGX) Tops Q2 Earnings, Raises 2024 Outlook
by Zacks Equity Research
Quest Diagnostics (DGX) delivers impressive base business growth in the second quarter of 2024.
Jobless Claims Increased More Than Expected
by Zacks Equity Research
Jobless Claims Increased More Than Expected
Abbott (ABT) Q2 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
Abbott (ABT) delivers a strong underlying base business performance in the second quarter of 2024.